138 related articles for article (PubMed ID: 36745014)
21. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial.
Hersey P; Coates AS; McCarthy WH; Thompson JF; Sillar RW; McLeod R; Gill PG; Coventry BJ; McMullen A; Dillon H; Simes RJ
J Clin Oncol; 2002 Oct; 20(20):4181-90. PubMed ID: 12377961
[TBL] [Abstract][Full Text] [Related]
22. Considering adjuvant therapy for stage II melanoma.
Poklepovic AS; Luke JJ
Cancer; 2020 Mar; 126(6):1166-1174. PubMed ID: 31869447
[TBL] [Abstract][Full Text] [Related]
23. [Treatment of melanoma with immune checkpoints inhibitors].
Lupu J; Hamann P; Routier É; Robert C
Rev Prat; 2021 Apr; 71(4):380-383. PubMed ID: 34161002
[TBL] [Abstract][Full Text] [Related]
24. Anti-PD1-Induced Immune-Related Adverse Events and Survival Outcomes in Advanced Melanoma.
Suo A; Chan Y; Beaulieu C; Kong S; Cheung WY; Monzon JG; Smylie M; Walker J; Morris D; Cheng T
Oncologist; 2020 May; 25(5):438-446. PubMed ID: 32048768
[TBL] [Abstract][Full Text] [Related]
25. Re-induction using whole cell melanoma vaccine genetically modified to melanoma stem cells-like beyond recurrence extends long term survival of high risk resected patients - updated results.
Mackiewicz J; Burzykowski T; Iżycki D; Mackiewicz A
J Immunother Cancer; 2018 Nov; 6(1):134. PubMed ID: 30486884
[TBL] [Abstract][Full Text] [Related]
26. Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial.
Eggermont AMM; Kicinski M; Blank CU; Mandala M; Long GV; Atkinson V; Dalle S; Haydon A; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo AM; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; Lorigan PC; Krepler C; Ibrahim N; Marreaud S; van Akkooi A; Robert C; Suciu S
JAMA Oncol; 2020 Apr; 6(4):519-527. PubMed ID: 31895407
[TBL] [Abstract][Full Text] [Related]
27. Adjuvant nodal field radiation in resected Stage III melanoma: A single-centre retrospective study in Christchurch, New Zealand.
Leong TW; McCook G; Frampton CM; Robinson BA; James ML
J Med Imaging Radiat Oncol; 2022 Oct; 66(7):1003-1013. PubMed ID: 35642730
[TBL] [Abstract][Full Text] [Related]
28. An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors.
O'Reilly A; Hughes P; Mann J; Lai Z; Teh JJ; Mclean E; Edmonds K; Lingard K; Chauhan D; Lynch J; Au L; Ludlow A; Pattison N; Wiseman T; Turajlic S; Gore M; Larkin J; Husson O
Support Care Cancer; 2020 Feb; 28(2):561-570. PubMed ID: 31089820
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant high-dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease.
Anaya DA; Xing Y; Feng L; Huang X; Camacho LH; Ross MI; Gershenwald JE; Lee JE; Mansfield PF; Cormier JN
Cancer; 2008 May; 112(9):2030-7. PubMed ID: 18320602
[TBL] [Abstract][Full Text] [Related]
30. Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy.
Attrill GH; Owen CN; Ahmed T; Vergara IA; Colebatch AJ; Conway JW; Nahar KJ; Thompson JF; Pires da Silva I; Carlino MS; Menzies AM; Lo S; Palendira U; Scolyer RA; Long GV; Wilmott JS
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688560
[TBL] [Abstract][Full Text] [Related]
31. Do Not Forget About the Importance of Loco-Regional Therapy in Melanoma Management.
Wuthrick EJ; Chablani P
Semin Radiat Oncol; 2019 Apr; 29(2):166-170. PubMed ID: 30827455
[TBL] [Abstract][Full Text] [Related]
32. The role of adjuvant therapy in melanoma management.
Barth A; Morton DL
Cancer; 1995 Jan; 75(2 Suppl):726-34. PubMed ID: 7805001
[TBL] [Abstract][Full Text] [Related]
33. BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy.
Barbour AP; Tang YH; Armour N; Dutton-Regester K; Krause L; Loffler KA; Lambie D; Burmeister B; Thomas J; Smithers BM; Hayward NK
Eur J Cancer; 2014 Oct; 50(15):2668-76. PubMed ID: 25070294
[TBL] [Abstract][Full Text] [Related]
34. [Adjuvant adoptive immunotherapy in patients with stage III and resected stage IV melanoma: a pilot study].
Verdecchia GM; Ridolfi L; Ridolfi R; Riccobon A; Bertagni A; Vagliasindi A; Petrini M; Stefanelli M; Milandri C; Amadori D
Tumori; 2003; 89(4 Suppl):298-300. PubMed ID: 12903626
[TBL] [Abstract][Full Text] [Related]
35. Generalized morphoea in the setting of combined immune checkpoint inhibitor therapy for metastatic melanoma: A case report.
Langan EA; Budner K; Zillikens D; Terheyden P
Medicine (Baltimore); 2021 Apr; 100(16):e25513. PubMed ID: 33879687
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome.
Sosman JA; Unger JM; Liu PY; Flaherty LE; Park MS; Kempf RA; Thompson JA; Terasaki PI; Sondak VK;
J Clin Oncol; 2002 Apr; 20(8):2067-75. PubMed ID: 11956267
[TBL] [Abstract][Full Text] [Related]
37. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial.
Wallack MK; Sivanandham M; Balch CM; Urist MM; Bland KI; Murray D; Robinson WA; Flaherty L; Richards JM; Bartolucci AA; Rosen L
J Am Coll Surg; 1998 Jul; 187(1):69-77; discussion 77-9. PubMed ID: 9660028
[TBL] [Abstract][Full Text] [Related]
38. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial.
Burmeister BH; Henderson MA; Ainslie J; Fisher R; Di Iulio J; Smithers BM; Hong A; Shannon K; Scolyer RA; Carruthers S; Coventry BJ; Babington S; Duprat J; Hoekstra HJ; Thompson JF
Lancet Oncol; 2012 Jun; 13(6):589-97. PubMed ID: 22575589
[TBL] [Abstract][Full Text] [Related]
39. Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival.
Carson WE; Unger JM; Sosman JA; Flaherty LE; Tuthill RJ; Porter MJ; Thompson JA; Kempf RA; Othus M; Ribas A; Sondak VK
Cancer Immunol Res; 2014 Oct; 2(10):981-7. PubMed ID: 24994597
[TBL] [Abstract][Full Text] [Related]
40. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.
Rose AAN; Armstrong SM; Hogg D; Butler MO; Saibil SD; Arteaga DP; Pimentel Muniz T; Kelly D; Ghazarian D; King I; Kamil ZS; Ross K; Spreafico A
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483342
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]